ProPhase Labs (PRPH)
(Real Time Quote from BATS)
$3.25 USD
+0.22 (7.26%)
Updated Jul 26, 2024 11:20 AM ET
3-Hold of 5 3
D Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PRPH 3.25 +0.22(7.26%)
Will PRPH be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PRPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PRPH
Ionis Pharmaceuticals (IONS) Reports Q1 Loss, Misses Revenue Estimates
Enanta Pharmaceuticals (ENTA) Reports Q2 Loss, Tops Revenue Estimates
PRPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
ProPhase Labs, Inc. (PRPH) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Strength Seen in Theravance Bio (TBPH): Can Its 7.6% Jump Turn into More Strength?
Adherex Technologies Inc. (FENC) Reports Q3 Loss, Tops Revenue Estimates
Other News for PRPH
ProPhase Labs Announces Update on Pharmaloz Manufacturing, Inc. Progress
Rare Stock Picks In May 2024 - From 29 Discerning Analysts
ProPhase Labs: Hidden Gem With An AI Kicker
ProPhase Labs Announces Financial Results for the Three Months Ended March 31, 2024, and Highlights Significant Progress in its Strategic Initiatives. - Updated
PRPH Stock Earnings: ProPhase Labs Beats EPS, Misses Revenue for Q1 2024